International Journal of Radiation Oncology * Biology * Physics
Volume 78, Issue 1 , Pages 42-49 , 1 September 2010

A Phase I/II Trial of Gefitinib Given Concurrently With Radiotherapy in Patients With Nonmetastatic Prostate Cancer

  • Greetta Joensuu, B.M.

      Affiliations

    • Cancer Gene Therapy Group, Molecular Cancer Biology Program and Transplantation Laboratory and Haartman Institute and Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland
    • International Comprehensive Cancer Center Docrates, Helsinki, Finland
    • ,
  • Timo Joensuu, M.D., Ph.D.

      Affiliations

    • International Comprehensive Cancer Center Docrates, Helsinki, Finland
    • ,
  • Petri Nokisalmi, M.Sc., B.M.

      Affiliations

    • Cancer Gene Therapy Group, Molecular Cancer Biology Program and Transplantation Laboratory and Haartman Institute and Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland
    • HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • Chandana Reddy, M.Sc.

      Affiliations

    • Radiation Oncology, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Jorma Isola, M.D., Ph.D.

      Affiliations

    • Institute of Medical Technology, University of Tampere, Tampere, Finland
    • ,
  • Mirja Ruutu, M.D., Ph.D.

      Affiliations

    • Department of Urology, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • Mauri Kouri, M.D., Ph.D.

      Affiliations

    • International Comprehensive Cancer Center Docrates, Helsinki, Finland
    • ,
  • Patrick A. Kupelian, M.D.

      Affiliations

    • Department of Radiation Oncology, M. D. Anderson Cancer Center Orlando, Orlando, Florida
    • ,
  • Juhani Collan, M.D.

      Affiliations

    • Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • Sari Pesonen, Ph.D.

      Affiliations

    • Cancer Gene Therapy Group, Molecular Cancer Biology Program and Transplantation Laboratory and Haartman Institute and Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland
    • HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • Akseli Hemminki, M.D., Ph.D.

      Affiliations

    • Cancer Gene Therapy Group, Molecular Cancer Biology Program and Transplantation Laboratory and Haartman Institute and Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland
    • HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
    • Corresponding Author InformationReprint requests to: Akseli Hemminki, Biomedicum, PO Box 63, 00014 University of Helsinki, Finland. Tel: (+358) 9 191 25 464; Fax: (+358) 9 1912 5465

Received 31 March 2009 ,Revised 20 July 2009 ,Accepted 22 July 2009.

References 

  1. Dutta PR, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett. 2007;254:165–177
  2. Ochs JS. Rationale and clinical basis for combining gefitinib (Iressa, ZD1839) with radiation therapy for solid tumors. Int J Radiat Oncol Biol Phys. 2004;58:941–949
  3. Cohen MH, Williams GA, Sridhara R, et al. United Sates Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res. 2004;10:1212–1218
  4. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet. 2008;372:1809–1818
  5. Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005;65:3328–3335
  6. Raben D, Helfrich BA, Chan D, et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002;29(Suppl. 4):37–46
  7. Williams K, Telfer B, Stratford I, et al. ZD1839 (“Iressa”), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Brit J Cancer. 2002;86:1157–1161
  8. Caponigro F, Romano C, Milano A, et al. A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. Anticancer Drugs. 2008;19:739–744
  9. Chen C, Kane M, Song J, et al. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol. 2007;25:4880–4886
  10. Maurel J, Martin-Richard M, Conill C, et al. Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2006;66:1391–1398
  11. Valentini V, Paoli AD, Gambacorta MA, et al. Infusional 5-fluorouracil and ZD1839 (gefitinib-IRESSA) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: A phase I and II trial (1839/0092). Int J Radiat Oncol Biol Phys. 2008;72:644–649
  12. Phuphanich S, Rudnick J, Chu R, et al. A phase I trial of gefitinib and sirolimus in adults with recurrent glioblastoma multiforme (GBM), abstract no. 2088. J Clin Oncol. 2008;26:
  13. Stinchcombe TE, Morris DE, Lee CB, et al. Induction chemotherapy with carboplatin, irinotecan and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J Thoracic Oncol. 2008;3:250–257
  14. Ma S, Xu Y, Deng Q, et al. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and gefitinib in a Chinese population. Lung Cancer. 2008;60:208–214
  15. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–354
  16. Shuch B, Mikhail M, Satagopan J, et al. Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol. 2004;22:4725–4729
  17. Torring N, Dagnaes-Hansen F, Sorensen BS, et al. ErbBI and prostate cancer: ErbBI activity is essential for androgen-induced proliferation and protection. Prostate. 2003;56:142–149
  18. Normanno N, DeLuca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366:2–16
  19. DiLorenzo G, Tortora G, D'Armiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res. 2002;8:3438–3444
  20. Schlomm T, Kirstein P, Iwers L, et al. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res. 2007;13:6579–6584
  21. Chen DJ, Nirodi CS. The epidermal growth factor receptor: A role in repair of radiation-induced DNA damage. Clin Cancer Res. 2007;13:6555–6560
  22. Rodemann HP, Dittmann K, Toulany M. Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol. 2007;83:781–791
  23. Dent P, Reardon DB, Park JS, et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell. 1999;10:2493–2506
  24. Akimoto T, Hunter NR, Buchmiller L, et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res. 1999;5:2884–2890
  25. Sheridan M, O'Dwyer T, Seymour C, et al. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig. 1997;5:180–186
  26. Schmidt-Ullrich R, Mikkelsen R, Dent P, et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene. 1997;15:1191–1197
  27. Schmidt-Ullrich R, Valerie K, Fogleman P, et al. Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat Res. 1996;145:81–85
  28. Carter S, Auer KL, Reardon DB, et al. Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. Oncogene. 1998;16:2787–2796
  29. Grandis JR, Drenning SD, Chakraborty A, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Investig. 1998;102:1385–1392
  30. Bandyopadhyay D, Mandal M, Adam L, et al. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem. 1998;273:1568–1573
  31. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  32. Kupelian P, Kuban D, Thames H, et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys. 2005;61:415–419
  33. Novocastra Laboratories Ltd. NCL-EGFR. Instructions for use. 2004.
  34. Isola J, Tanner M, Forsyth A, et al. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res. 2004;10:4793–4798
  35. Kimura H, Kasahara K, Sekijima M, et al. Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor gefitinib. Lung Cancer. 2005;20:393–399
  36. Kovacs CJ, Daly BM, Evans MJ, et al. Cytokine profiles in patients receiving wide-field plus prostate boost radiotherapy (xRT) for adenocarcinoma of the prostate. Cytokine. 2003;23:151–163
  37. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol. 2002;20:2240–2250
  38. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:2237–2246
  39. Costa DB, Kobayashi S, Tenen DG, et al. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer. 2007;58:95–103
  40. Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Brit J Cancer. 2006;95:998–1004
  41. Sutani A, Nagai Y, Udagawa K, et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Brit J Cancer. 2006;95:1483–1489
  42. Small EJ, Fontana J, Tannir N, et al. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int. 2007;100:765–769
  43. Canil CM, Moore MJ, Winquist E, et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol. 2005;23:455–460
  44. Schwer AL, Damek DM, Kavanagh BD, et al. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2008;70:993–1001
  45. Gravina GL, Festuccia C, Galatioto GP, et al. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer. Urology. 2007;70:728–733
  46. Olapade-Olaopa E, Moscatello D, MacKay E, et al. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Brit J Cancer. 2000;82:186–194

 Greetta Joensuu and Timo Joensuu contributed equally to this work.

 This study was supported by AstraZeneca, HUCH Research Funds (EVO), Finnish Cancer Society, Sigrid Juselius Foundation, Academy of Finland, Biocentrum Helsinki and University of Helsinki.

 Conflict of interest: none.

PII: S0360-3016(09)02918-6

doi: 10.1016/j.ijrobp.2009.07.1731

International Journal of Radiation Oncology * Biology * Physics
Volume 78, Issue 1 , Pages 42-49 , 1 September 2010

Article Tools

* Image Usage & Resolution